Nilanjan Ghosh, MD, PhD

Articles

Emerging Updates in Front-line Treatment Approach of DLBCL

January 3rd 2025

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

June 27th 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL

April 5th 2021

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL

December 1st 2020

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies

September 14th 2020

Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.

Dr. Ghosh on Unanswered Questions With BTK Inhibitors in CLL/SLL

September 10th 2020

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Ghosh on Differences Among Available BTK Inhibitors in B-Cell Malignancies

August 18th 2020

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Dr. Ghosh on Global Trials With Zanubrutinib in MCL and NHL

August 14th 2020

Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

Dr. Ghosh on the Role of MRD in CLL

August 12th 2020

Nilanjan Ghosh, MD, PhD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Dr. Ghosh on the Benefits of Lisocabtagene Maraleucel in Relapsed/Refractory NHL

July 31st 2020

Nilanjan Ghosh, MD, PhD, discusses the utility of lisocabtagene maraleucel in relapsed/refractory non-Hodgkin lymphoma.

Dr. Ghosh on Safety Results From the Phase 2 PILOT Trial in Non-Hodgkin Lymphoma

July 23rd 2020

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Dr. Ghosh on Efficacy Results from the Phase 2 PILOT trial in Non-Hodgkin Lymphoma

June 25th 2020

Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.

Dr. Ghosh on the Need to Develop Novel Therapies in DLBCL

June 18th 2020

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

Dr. Ghosh on the Role of Bleomycin in Hodgkin Lymphoma

June 6th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.

Dr. Ghosh on Frontline Immunotherapy in Hodgkin Lymphoma

May 17th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses frontline immunotherapy in Hodgkin lymphoma.

Dr. Ghosh on the Future of CAR T-Cell Therapy in Patients With Hematologic Malignancies

May 7th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with hematologic malignancies.

Dr. Ghosh on PET-Adapted Therapy in Patients With Hodgkin Lymphoma

April 28th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.